Immutep Faces Multiple Class Actions
Analysis based on 87 articles · First reported May 18, 2026 · Last updated Jun 11, 2026
The multiple class action lawsuits against Immutep for alleged securities fraud have already caused a dramatic decline in Immutep's stock price, with shares falling by approximately 83%. This event creates significant uncertainty for Immutep's future and could lead to substantial financial penalties and reputational damage, impacting investor confidence in the biotechnology sector.
Multiple investor-rights law firms, including Bronstein, Gewirtz & Grossman, LLC, The Schall Law Firm, Robbins LLP, The Gross Law Firm, and Pomerantz LLP, have filed class action lawsuits against Immutep Limited and its officers. These lawsuits allege violations of federal securities laws, claiming that Immutep made materially false and misleading statements regarding the status and prospects of its TACTI-004 clinical trial. Specifically, the complaints state that Immutep concealed and misrepresented the trial's progress, relying on prior positive results from other studies (TACTI-002 and INSIGHT-003) to suggest continued success, despite internal data indicating an increased risk of the trial failing to meet its primary efficacy and/or safety endpoints. The company's statements in a Form-K filed with the United States — United States Securities and Exchange Commission on January 30, 2026, claiming 'strong operational progress' for the TACTI-004 trial, are cited as misleading. On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study due to futility, leading to an 83% drop in Immutep's American Depositary Receipt price. Investors who purchased Immutep securities between March 24, 2025, and March 12, 2026, are encouraged to join these lawsuits, with a lead plaintiff deadline of July 6, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard